Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CVac: Phase II final data

Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD), Sydney, Australia
Product: CVac
Business: Cancer
Molecular target: Mucin 1 (MUC1) (CD227)
Description: Ex vivo cancer vaccine

Read the full 224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE